Illustrative image.
Terlivaz
Terlipressin (acetate)
$205.00
1mg · 1 ampules
BrandBranded medicine· By Ferring
Strength
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
1mg/5ml
1mg
FDA boxed warningSerious or fatal respiratory failure
TERLIVAZ may cause serious or fatal respiratory failure. Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk. Assess oxygenation saturation (e.g., SpO 2 ) before initiating TERLIVAZ.
Do not initiate TERLIVAZ in patients experiencing hypoxia (e.g., SpO 2 <90%) until oxygenation levels improve. Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue TERLIVAZ if SpO 2 decreases below 90%.
TERLIVAZ may cause serious or fatal respiratory failure. Patients with volume overload or with ACLF Grade 3 are at increased risk. Assess oxygenation saturation (e.g., SpO 2 ) before initiating TERLIVAZ.
About Terlivaz
Overview
Terlivaz contains terlipressin, a vasopressin receptor agonist. It is used to improve kidney function in adults with hepatorenal syndrome whose kidney function is rapidly worsening. It is thought to improve blood flow to the kidneys by reducing pressure and circulation in the portal blood vessels and increasing blood pressure in the arteries. Patients with a serum creatinine level above 5 mg/dL are unlikely to benefit.
What it treats
Hepatorenal syndrome with a rapid decline in kidney function in adults, to improve kidney function. Patients with serum creatinine above 5 mg/dL are unlikely to benefit.
Safety information
Side effects
Common side effects include abdominal pain, nausea, diarrhea, shortness of breath and respiratory failure. Respiratory failure is common but serious and can be fatal. Seek immediate medical attention for breathing problems. Terlivaz can also narrow blood vessels and reduce blood flow to the heart, limbs or intestines. These serious effects require prompt medical assessment and may require treatment to be interrupted or stopped. Terlivaz-related adverse reactions may make someone on a liver transplant waiting list ineligible for transplantation. Terlivaz may also harm an unborn baby; contact your doctor if you are pregnant or become pregnant during treatment.
FDA boxed warning
Serious or fatal respiratory failure
TERLIVAZ may cause serious or fatal respiratory failure. Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk. Assess oxygenation saturation (e.g., SpO 2 ) before initiating TERLIVAZ.
Do not initiate TERLIVAZ in patients experiencing hypoxia (e.g., SpO 2 <90%) until oxygenation levels improve. Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue TERLIVAZ if SpO 2 decreases below 90%.
TERLIVAZ may cause serious or fatal respiratory failure. Patients with volume overload or with ACLF Grade 3 are at increased risk. Assess oxygenation saturation (e.g., SpO 2 ) before initiating TERLIVAZ.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Terlivaz must not be used in people with low blood oxygen, worsening breathing symptoms, or an ongoing lack of blood flow to the heart, limbs or intestines. Terlivaz can cause serious or fatal respiratory failure. Blood oxygen levels and breathing must be monitored during treatment. Excess fluid in the bloodstream requires active management, and treatment may need adjustment. Terlivaz narrows blood vessels and can reduce blood flow to the heart, limbs or intestines, which may require treatment to be paused or stopped. Side effects may also make someone on a liver transplant waiting list ineligible for transplantation. Terlivaz may harm an unborn baby if used during pregnancy. People who could become pregnant should be informed of this risk.
Using Terlivaz
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light. Do not freeze, and use immediately once opened. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label TERLIVAZ (TERLIPRESSIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [MALLINCKRODT HOSPITAL PRODUCTS INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Urocit‑K
Potassium Citrate
By Mission Pharmacal
Tablets · from 1 per pack
Also for kidney disease
Brand $91.00
Renvela
Sevelamer Carbonate
By Sanofi
Tablets · from 180 per pack
Also for kidney disease
Brand $463.00
Velphoro
Sucroferric oxyhydroxide
By C.T.S
Chewable Tablets · from 90 per pack
Also for kidney disease
Brand $261.00
Kerendia
Finerenone
By Bayer
Tablets · from 28 per pack
Also for kidney disease
Brand $121.00